Ernexa Therapeutics Inc. has announced the pricing of a public offering consisting of 21,000,000 shares of its common stock (or common stock equivalents) and warrants to purchase up to 21,000,000 shares of common stock. The combined public offering price is $0.50 per share and accompanying warrant. The warrants have an exercise price of $0.68 per share, are exercisable upon issuance, and will expire on the earlier of five years from the issuance date or 180 days after the public release of clinical trial data from the first cohort of the Phase 1 study of ERNA-101. The gross proceeds from the offering are expected to be approximately $10.5 million, with potential additional proceeds of $14.3 million if all warrants are exercised. Ernexa intends to use the net proceeds to advance its development programs, for working capital, and for general corporate purposes.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ernexa Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-006227), on February 11, 2026, and is solely responsible for the information contained therein.